Topotecan treatment and its toxic effects on hematologic parameters and trace elements

Basit Öğe Kaydı
dc.contributor.authorHizel, Selda Buelbuel
dc.contributor.authorSanli, Cihat
dc.contributor.authorMuluk, Nuray Bayar
dc.contributor.authorAlbayrak, Meryem
dc.contributor.authorOzyazici, Ahmet
dc.contributor.authorApan, Alpaslan
dc.date.accessioned2020-06-25T17:44:25Z
dc.date.available2020-06-25T17:44:25Z
dc.date.issued2008
dc.departmentKırıkkale Üniversitesi
dc.descriptionAlbayrak, Meryem/0000-0003-2711-5150
dc.description.abstractThe aim of this study was to investigate the effects of topotecan, a topoisomerase I-inhibiting anticancer agent, on hematologic parameters and serum levels of trace elements. The study was conducted on three groups consisting of 16 and 18 rabbits in the study groups and 15 rabbits in the control group. Rabbits in group I (n=16) received high-dose topotecan intravenously (i.v.; 0.5 mg/kg once daily), while rabbits in group II (n=18) received low-dose topotecan i.v. (0.25 mg/kg once daily) for 3 days. The 15 rabbits comprising the control group did not receive topotecan. Serum samples were collected from each rabbit on the first day, before the treatment, and on the 15th day of treatment. Erithrocytes, hemoglobin, white blood cell count, thrombocyte count, and trace elements such as selenium, copper, lead, zinc, and cobalt were analyzed. Hemoglobin levels and erythrocyte counts were lower in both study groups than in the control group. However, thrombocyte and leukocyte counts were similar in all three groups (p > 0.005). Serum trace element levels (copper, lead, zinc, and cobalt) did not differ significantly between groups. However, serum selenium levels were significantly lower in both study groups than the control group (p < 0.001). The results revealed that topotecan treatment causes a decrease in erythrocyte counts and hemoglobin levels due to bone marrow suppression, and these effects must be taken into account during treatment. In addition, selenium supplementation might be helpful in cancer patients receiving topotecan to increase the effect of the chemotherapeutic agent.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1007/s12011-008-8140-9
dc.identifier.endpage134en_US
dc.identifier.issn0163-4984
dc.identifier.issue2en_US
dc.identifier.pmid18498005
dc.identifier.scopus2-s2.0-55549140844
dc.identifier.scopusqualityQ1
dc.identifier.startpage129en_US
dc.identifier.urihttps://doi.org/10.1007/s12011-008-8140-9
dc.identifier.urihttps://hdl.handle.net/20.500.12587/4104
dc.identifier.volume124en_US
dc.identifier.wosWOS:000259003900005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherHumana Press Incen_US
dc.relation.ispartofBiological Trace Element Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecttopotecanen_US
dc.subjecttrace elementsen_US
dc.subjectmyelosuppressionen_US
dc.titleTopotecan treatment and its toxic effects on hematologic parameters and trace elementsen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Topotecan treatment and its toxic effects on hematologic parameters and trace elements.pdf
Boyut:
98.38 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu